Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation

被引：1
|
作者：
Lindley, Richard, I [1 ,2 ]
机构：
[1] Univ Sydney, Fac Med & Hlth, Westmead Appl Res Ctr, Camperdown, NSW, Australia
[2] George Inst Global Hlth, Sydney, NSW, Australia
来源：
AUSTRALIAN PRESCRIBER | 2021年 / 44卷 / 02期
关键词：
anticoagulants; apixaban; atrial fibrillation; dabigatran; haemorrhage; rivaroxaban; thromboembolism;
D O I：
10.18773/austprescr.2021.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Non-valvular atrial fibrillation is becoming more common in Australia and globally. The direct oral anticoagulants apixaban, dabigatran and rivaroxaban offer an improved safety profile over warfarin. Patient preferences are important and shared decision-making supports better adherence to treatment.
引用
收藏
页码：49 / 52
页数：4
相关论文
共 50 条
  • [1] Effectiveness and safety of oral anticoagulation treatment with acenocoumarol in non-valvular atrial fibrillation
    Castro, Constanza
    Bustos, Luis
    Ocampo, Renato
    Molina, Elda
    Cabrero, Pia
    Vergara, Rene
    Lanas, Fernando
    [J]. REVISTA MEDICA DE CHILE, 2017, 145 (10) : 1243 - 1251
  • [2] Oral anticoagulation in patients with hypertrophic cardiomyopathy and non-valvular atrial fibrillation in Japan
    Kitaoka, Hiroaki
    Carroll, Robert
    Eugene, Natalie
    Teixeira, Bruno Casaes
    Matsuo, Yukako
    Kubo, Toru
    [J]. ESC HEART FAILURE, 2024,
  • [3] New Era of Oral Anticoagulation for Japanese Non-Valvular Atrial Fibrillation Patients
    Hirano, Teruyuki
    [J]. CIRCULATION JOURNAL, 2014, 78 (06) : 1317 - 1319
  • [4] Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
    Dhamane, Amol D.
    Hernandez, Inmaculada
    Di Fusco, Manuela
    Gutierrez, Cynthia
    Ferri, Mauricio
    Russ, Cristina
    Tsai, Wan-Lun
    Emir, Birol
    Yuce, Huseyin
    Keshishian, Allison
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (03) : 333 - 343
  • [5] Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
    Amol D Dhamane
    Inmaculada Hernandez
    Manuela Di Fusco
    Cynthia Gutierrez
    Mauricio Ferri
    Cristina Russ
    Wan-Lun Tsai
    Birol Emir
    Huseyin Yuce
    Allison Keshishian
    [J]. American Journal of Cardiovascular Drugs, 2022, 22 : 333 - 343
  • [6] Non-persistence to Oral Anticoagulation Therapy in Elderly Patients with Non-valvular Atrial Fibrillation
    Cao, Yue
    Feng, Yue-Yue
    Du, Wei
    Li, Jing
    Fei, Ya-Lan
    Yang, Hao
    Wang, Meng
    Li, Shi-Jie
    Li, Xian-Jin
    Han, Bing
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 3185 - 3194
  • [7] Persistence to Oral Anticoagulation Treatment in Non-valvular Atrial Fibrillation Patients in the United States
    Dhamane, Amol
    Di Fusco, Manuela
    Gutierrez, Cynthia
    Ferri, Mauricio
    Russ, Cristina
    Tsai, Wan-Lun
    Emir, Birol
    Keshishian, Allison
    [J]. CIRCULATION, 2020, 142
  • [8] Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents
    Kepez, Alper
    Erdogan, Okan
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2013, 13 (04): : 379 - 384
  • [9] Anticoagulation in Non-Valvular Atrial Fibrillation: Underused or Wrongly Used?
    Escobar, Carlos
    Barrios, Vivencio
    Calderon, Alberto
    Roldan, Cecilia
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (11): : 1687 - 1688
  • [10] Novel oral anticoagulants in non-valvular atrial fibrillation
    Potpara, Tatjana S.
    Lip, Gregory Y. H.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 115 - 129
12345